Browse the evidence

GLP-1 receptor agonists decrease weight in people with schizophrenia.

GLP-1 receptor agonists may be considered as a treatment option for weight management in patients with schizophrenia.

Newer antiobesity pharmacotherapies, particularly semaglutide and tirzepatide, have shown greater efficacy for weight reduction compared with older medications.

Newer medications may provide better options for weight management in patients with obesity.

Retatrutide resulted in a percentage change in weight from baseline to 24 weeks ranging from -7.2% to -~18% as the dose increased from 1 mg to 12 mg.

Retatrutide may be an effective treatment option for weight loss in individuals with obesity.

Semaglutide 2.4 mg was associated with significantly greater weight loss compared to placebo in clinical trials lasting 68 weeks.

Semaglutide can be considered an effective pharmacotherapy for weight loss in adults with obesity or overweight.

NN1706 treatment led to 8.2% weight loss from baseline after 10 weeks in adults with overweight/obesity.

NN1706 may be an effective treatment option for weight loss in adults with overweight or obesity.

Effective obesity management is essential to mitigate associated comorbidities and improve quality of life in menopausal women.

Healthcare providers should prioritize obesity management in menopausal women to enhance their health outcomes.

Tailored treatment strategies are necessary to address the unique challenges of obesity management during menopause.

Practitioners should develop individualized obesity management plans for menopausal women.

Tirzepatide resulted in greater hemoglobin A1c reduction from baseline compared to placebo and active comparators, with absolute reductions up to 3.02%.

Tirzepatide may be a more effective option for lowering blood sugar in patients with type 2 diabetes.

Tirzepatide was associated with significant weight loss.

Tirzepatide may aid in weight management for patients with type 2 diabetes.

Tirzepatide shows great efficacy in glycosylated hemoglobin and weight reduction.

Tirzepatide may be effective for improving glycemic control and promoting weight loss in diverse patient groups.

GLP-1 receptor agonists (GLP-1 RAs) have shown promising potential in promoting weight loss and preventing diseases associated with obesity.

GLP-1 RAs may be considered as a pharmacologic option for obesity treatment.

Semaglutide and liraglutide have been approved as weight loss medications due to their effectiveness in promoting significant and sustained weight loss.

Clinicians can prescribe semaglutide and liraglutide for weight management in eligible patients.

GLP-1 agonists resulted in a percentage of change in body weight of -6.2% at six months.

GLP-1 agonists may be an effective option for weight loss in obese IBD patients.

58.3% of patients achieved a weight reduction of 5% or more at six months.

A significant portion of obese IBD patients may benefit from GLP-1 agonist therapy for weight loss.

Semaglutide is effective for weight loss in obese or overweight patients.

Semaglutide can be considered as a treatment option for weight management in obese or overweight patients.

Incretin-based therapies resulted in significant reductions in body weight and/or body mass index in patients with obstructive sleep apnea.

Practitioners may consider incretin-based therapies as effective options for weight management in OSA patients.

Tirzepatide has demonstrated significant body weight reductions in individuals with obesity but not diabetes.

Tirzepatide may be beneficial for weight management in patients with obesity.

Semaglutide is safe and effective for weight loss in obese, non-diabetic patients with end-stage kidney disease on haemodialysis.

Practitioners may consider semaglutide as a treatment option for weight loss in similar patient populations.

Semaglutide, a GLP-1 receptor agonist, demonstrated much greater weight loss than previous medications.

Practitioners may consider semaglutide as a more effective option for weight loss in obese patients.

GLP-1RA use in patients with metabolically unhealthy obesity (MUHO) is associated with a significantly lower risk of mortality (HR 0.580) compared to non-use.

Clinicians may consider GLP-1RAs for reducing mortality risk in MUHO patients.

Anti-obesity medications, particularly glucagon-like peptide-1 receptor agonists, have shown safety and weight loss efficacy in patients with heart failure with preserved ejection fraction.

Clinicians may consider glucagon-like peptide-1 receptor agonists for weight management in patients with heart failure with preserved ejection fraction.

Carbohydrate intake measures showed strong associations with weight loss at 3-, 6-, and 12-month time points.

Focusing on carbohydrate intake may enhance weight loss efforts.

Weight loss in both diet groups seems to have been driven by the reduction of glycemic load (GL) more so than dietary fat or calories.

Reducing glycemic load may be more effective for weight loss than focusing solely on fat or calorie reduction.

Tirzepatide has demonstrated superior weight loss efficacy compared to previously approved medications.

Tirzepatide may be considered as a more effective pharmacotherapy option for weight loss in patients compared to existing medications.